Bayer has previously invested about €1.3bn in more than 50 companies in the past seven years.

Leaps by Bayer, the corporate venturing unit of Germany-based drugs and crops company Bayer, has committed a further €1.3bn ($1.44bn) over the next three years to more than double the pace of spending to date. The new investment plan was announced last month with a focus on cell and gene therapy (CGT) and precision health for consumers…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.